Aerobic Exercises for Multiple Sclerosis

September 3, 2020 updated by: Nehad Ahmed Youness Abo-zaid, South Valley University

Effect of Aerobic Exercises on Immune System in Patients With Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) .It is the most common neurological disorders affecting young adults.Multiple sclerosis is an autoimmune disease that results in progressive neural degeneration. Cytokines play an important role in the pathogenesis and treatment of MS.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This research aims to evaluate the effect of aerobic exercises on the immune system anti-inflammatory (IL-10) and pro inflammatory (IL-17) cytokines and its consequences on the functional status in the Multiple Sclerosis patients.

Aerobic exercises are a term to describe planned, structured and repetitive physical activity undertaken over a prolonged period to maintain or improve physical fitness and functional capacity .

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Qina,, Egypt, 83523
        • South Valley University, Faculty of Physical Therapy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 45 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

age ranged from 25 to 45 years. All the patients were remitting relapsing MS according to (revised McDonald criteria.

Duration of MS disease was one to two years before starting of the study. Last attack occurred three months ago. All patients were able to ambulate

Exclusion Criteria:

Patients with other neurological deficits , patient with significant orthopedic abnormalities for both lower limbs, patient with contracture , patient with deformities, pregnant females

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: the study group
the study group (GA) was treated only by the disease modifying drug (interferon beta-1a) in addition to aerobic exercise.
Other: aerobic exercise
NO_INTERVENTION: the control group
control group (GB)was treated only by the disease modifying drug (interferon beta-1a)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
blood analysis
Time Frame: serum anti inflammatory cytokine IL-10, will be assessed at 0 day
serum anti inflammatory cytokine IL-10,
serum anti inflammatory cytokine IL-10, will be assessed at 0 day
blood analysis
Time Frame: serum anti inflammatory cytokine IL-10, wil lbe assessed at 90 day
serum anti inflammatory cytokine IL-10,
serum anti inflammatory cytokine IL-10, wil lbe assessed at 90 day
blood analysis
Time Frame: pro inflammatory cytokine IL-17 will be assessed at 0 day
pro inflammatory cytokine IL-17
pro inflammatory cytokine IL-17 will be assessed at 0 day
blood analysis
Time Frame: pro inflammatory cytokine IL-17 will be assessed at 90 day
pro inflammatory cytokine IL-17
pro inflammatory cytokine IL-17 will be assessed at 90 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

South Valley University

Investigators

  • Principal Investigator: Heba A. Kalifa, Ph.D, Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 2, 2015

Primary Completion (ACTUAL)

August 4, 2018

Study Completion (ACTUAL)

August 6, 2020

Study Registration Dates

First Submitted

August 26, 2020

First Submitted That Met QC Criteria

September 3, 2020

First Posted (ACTUAL)

September 11, 2020

Study Record Updates

Last Update Posted (ACTUAL)

September 11, 2020

Last Update Submitted That Met QC Criteria

September 3, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P.T.REC/012/001072

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis, Primary Progressive

Clinical Trials on aerobic exercise

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe